Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 5, 1998, Pages 1176-1180

  Carr, Robert A ^a   Edmonds, Anthony ^b   Shi, Harry ^a   Locke, Charles S ^a   Gustavson, Linda E ^a   Craft, J Carl ^a   Harris, Stuart I ^c,d   Palmer, Robert ^a  

^a ABBOTT LABORATORIES   (United States)

^b TAP Holdings Inc   (United States)

^c South Florida Bioavailability Clinic   (United States)

^d Seaview Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYCLARITHROMYCIN; CLARITHROMYCIN; CYTOCHROME P450; LORATADINE;

ADULT; ADVERSE DRUG REACTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HUMAN; LIVER CLEARANCE; LIVER METABOLISM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; STEADY STATE;

EID: 0031971093     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.5.1176     Document Type: Article

References (19)

1. Affrime, M. B., R. Lorber, M. Danzig, F. Cuss, and M. D. Brannan. 1993. Three month evaluation of electrocardiographic effects of loratadine in humans. J. Allergy Clin. Immunol. 91:259.
2. Benedict, C. R. 1993. The QT interval and drug-associated torsades de pointes. Drug Invest. 5:69-79.
3. Brannan, M. D., P. Reidenberg, E. Radwanski, L. Shneyer, C. C. Lin, M. N. Cayen, and M. B. Affrime. 1995. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin. Pharmacol. Ther. 58:269-278.
4. Chu, S. Y., L. T. Sennello, and R. C. Sonders. 1991. Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 571:199-208.
5. Chu, S. Y., D. S. Wilson, R. L. Deaton, A. V. Mackenthun, C. N. Eason, and J. H. Cavanaugh. 1993. Single-and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol. 33:719-726.
6. Clissold, S. P., E. M. Sorkin, and K. L. Goa. 1989. Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 37: 42-57.
7. Descotes, J., P. Andre, and J. C. Evreux. 1985. Pharmacokinetic drug interactions with macrolide antibiotics. J. Antimicrob. Chemother. 15:659-664.
8. Gascon, M. P., and P. Dayer. 1991. Comparative effects of macrolide antibiotics on liver monoxygenases. Clin. Pharmacol. Ther. 49:158.
9. Gustavson, L. E., J. F. Kaiser, A. L. Edmonds, and C. Locke. 1995. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob. Agents Chemother. 39:2078-2083.
10. Hey, J. A., M. del Prado, R. W. Egan, J. Sherwood, and W. Kreutner. 1995. Loratadine produces antihistamine activity without adverse CNS, ECG or cardiovascular effects in guinea pigs. Comparative studies with terfenadine and sedating antihistamines. Int. Arch. Allergy Immunol. 107:418-419.
11. Hilbert, J., E. Radwanski, R. Weglein, V. Luc, G. Perentesis, S. Symchowicz, and N. Zampaglione. 1987. Pharmacokinetics and dose proportionality of loratadine. J. Clin. Pharmacol. 27:694-698.
12. Honig, P. K., D. C. Wortham, K. Zamani, and L. R. Cantilena. 1994. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest. 7:148-156.
13. Katchen, B., J. Cramer, M. Chung, R. Gural, J. Hilbert, V. Luc, V. Mortizen, R. D'Souza, S. Symchowicz, and N. Zampaglione. 1985. Disposition of 14C-SCH 29851 in humans. Ann. Allergy 55:393.
14. Morganroth, J., F. V. Brozovich, J. T. McDonald, and R. A. Jacobs. 1991. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am. J. Cardiol. 67:774-776.
15. Periti, P., T. Mazzei, E. Mini, and A. Novelli. 1992. Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 23:106-131.
16. Radwanski, E., J. Hilbert, S. Symchowicz, and N. Zampaglione. 1987. Loratadine: multiple-dose pharmacokinetics. J. Clin. Pharmacol. 27:530-533.
17. Siepman, N., K. S. Blahunka, S. I. Harris, and R. N. Palmer. 1993. ECG changes observed following multiple dose co-administration of clarithromycin (C) and terfenadine (T). Pharm. Res. 10:S354.
18. Woosley, R. L., Y. Chen, J. P. Freiman, and R. A. Gillis. 1993. Mechanism of the cardiotoxic actions of terfenadine. JAMA 269:1532-1536.
19. Yumibe, N., K. Huie, K. J. Chen, M. Snow, R. P. Clement, and M. N. Cayen. 1996. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem. Pharmacol. 51:165-172.